Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pantelis Dimaras

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Folia Medica|August 31, 2022
Improving gene expression analysis efficacy from formalin-fixed paraffin embedded tissuesPantelis Dimaras, Oskan Tasinov, Desislava Ivanova, et al.
Expert Review of Molecular Diagnostics|January 9, 2024
Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla<sup>TM</sup> platform: a real-world two-center experience in GreeceKleita Michaelidou, Ioannis Karniadakis, Varvara Pantelaion, et al.
Future Oncology (London, England)|September 15, 2025
Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort studyElias Kotteas, Εmmanouil Panagiotou, Μaria Grammoustianou, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Folia Medica|August 31, 2022
Improving gene expression analysis efficacy from formalin-fixed paraffin embedded tissuesPantelis Dimaras, Oskan Tasinov, Desislava Ivanova, et al.
Expert Review of Molecular Diagnostics|January 9, 2024
Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla<sup>TM</sup> platform: a real-world two-center experience in GreeceKleita Michaelidou, Ioannis Karniadakis, Varvara Pantelaion, et al.
Future Oncology (London, England)|September 15, 2025
Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort studyElias Kotteas, Εmmanouil Panagiotou, Μaria Grammoustianou, et al.
Pageof 1